Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 97; no. 5; pp. E168 - E171
Main Authors Allsup, David John, Craig, Zoe, Cairns, David, Howard, Dena, Hockaday, Anna, Bloor, Adrian, Soe, Zarni, Pepper, Christopher, Gattei, Valter, Zucchetto, Antonella, Robbe, Pauline, Clifford, Ruth, Schuh, Anna, Munir, Talha, Rawstron, Andrew, Hillmen, Peter
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.05.2022
Wiley Subscription Services, Inc
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chronic lymphocytic leukemia
Clinical trials
Cyclophosphamide
Fludarabine
Follow-Up Studies
Hematology
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Lymphatic leukemia
Prognosis
Rituximab
Treatment Outcome
Vidarabine - analogs & derivatives
Online AccessGet full text

Cover

More Information
Bibliography:Funding information
David John Allsup and Zoe Craig co‐first authors.
Health Technology Assessment Programme; Associazione Italiana Ricerca Cancro, Grant/Award Number: IG‐21687; Progetto Ricerca Finalizzata, Grant/Award Numbers: RF‐2018‐12365790, PE‐2016‐02362756; Core Clinical Trials Unit Infrastructure, Grant/Award Number: C7852/A25447; Roche Products Ltd
SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.26483